<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170987</url>
  </required_header>
  <id_info>
    <org_study_id>1160.54</org_study_id>
    <nct_id>NCT02170987</nct_id>
  </id_info>
  <brief_title>Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.</brief_title>
  <official_title>Assessment of Electrophysiological Effects of 150 mg and 600 mg of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind Three-way Crossover Study With an Open Label Positive Control (Moxifloxacin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate if dabigatran has a clinically relevant impact on the cardiac
      electrophysiology that is manifest as prolongation in QT-interval.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean time-matched QTc Interval</measure>
    <time_frame>at 1.5, 2, and 3 hours following administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean of the QTcI values of all ECGs</measure>
    <time_frame>from 1 to 6 hours following administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the QTcI</measure>
    <time_frame>from 1 to 24 hours following administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dabigatran etexilate low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran etexilate high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to dabigatran etexilate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate low</intervention_name>
    <arm_group_label>Dabigatran etexilate low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran etexilate high</intervention_name>
    <arm_group_label>Dabigatran etexilate high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo to dabigatran etexilate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy female (at least 1/3) and male (at least 1/3) volunteers as determined by the
             results of screening according to the following criteria: Based upon a complete
             medical history, including the physical examination, vital signs (BP, HR), 12-lead
             ECG, clinical laboratory tests

          2. Age &gt;= 18 and Age &lt;= 65 years

          3. BMI &gt;= 20.0 and BMI &lt;=29.9 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion Criteria:

          1. Any finding of the medical examination (including BP, pulse rate (PR) and ECG)
             deviating from normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          8. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          9. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to administration
             or during the trial

         10. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         11. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

         12. Inability to refrain from smoking on trial days

         13. Alcohol abuse (more than 60 g/day)

         14. Drug abuse

         15. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         16. History of any bleeding disorder or acute blood coagulation defect

         17. Hypersensitivity to moxifloxacin and/or related drugs of this class

         18. Excessive physical activities (within one week prior to administration or during the
             trial)

         19. Any laboratory value outside the reference range that is of clinical relevance

         20. Inability to comply with dietary regimen of study centre

         21. History of additional risk factors for Torsade des Pointes (e.g. heart failure,
             hypokalemia, family history of long QT syndrome)

         22. Any screening ECG value outside of the reference range of clinical relevance
             including, but not limited to heart rate of &gt;80 bpm or &lt;45 bpm, PR interval &gt;220 ms,
             QRS interval &gt;120 ms, QT interval &gt;470 ms or QTcB or QTcF &gt;450 ms

             For female subjects:

         23. Pregnancy

         24. Positive pregnancy test

         25. No adequate contraception e.g. oral contraceptives, sterilisation, intrauterine device
             (IUD)

         26. Inability to maintain this adequate contraception during the whole study period

         27. Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

